Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vermillion and Stanford University to develop cardiac biomarker
Under the terms of the agreement, Vermillion is granted exclusive rights to the biomarker panel, and will undertake the development and commercialization of a PAD blood test, which
Under the terms of the agreement, Vermillion is granted exclusive rights to the biomarker panel, and will undertake the development and commercialization of a PAD blood test, which
If, as anticipated, ABI’s new study demonstrates the efficacy and safety of this treatment regimen, ABI intends to conduct a Phase III study before filing a marketing approval
The experiments performed used a process called RNA interference (RNAi) to specifically ‘silence’ the expression of Boris in cancer cells. The results demonstrated that the cancer cells in
Provista Life Sciences has recently announced the availability of its Biomarker Translation test or BT test, a blood test specifically designed to assist physicians and other healthcare providers
Under the agreement, LifeNet Health will provide Etex with demineralized bone matrix (DBM) powder to be mixed with Etex’s proprietary calcium phosphate to form a bone graft substitute
The device will enable men to test their post-vasectomy fertility status at home rather than requiring the patient to return to the physician’s office or a laboratory. Physicians
The subpoena broadly requests documents regarding promotional, educational and other activities relating to Botox. The company’s current understanding is that the inquiry involves questions regarding alleged off label
The advantage of this assay over other formats is that it generates a positive readout in direct proportion to ADP accumulated. This is particularly useful in determining kinase
In an analysis of hot flashes in a subset of patients in the Phase III ADT clinical trial experiencing six or more hot flashes per day at baseline
Under the terms of the expanded license agreement, BioWa will grant to Genentech commercial rights to research, develop, manufacture and commercialize antibodies utilizing Potelligent Technology for an additional